Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin Deficiency

R. C. Hubbard, S. Sellers, D. Czerski, L. Stephens, Ronald Crystal

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

The hereditary disorder α1-antitrypsin (α1AT) deficiency results in the development of emphysema due to a diminished anti—neutrophil elastase screen of the lower respiratory tract. Specific therapy for this disorder is available in the form of weekly intravenous infusions of human plasma α1AT, which effectively reconstitute the anti-elastase screen of the lung in these individuals. In an attempt to reduce the frequency of therapy we evaluated the ability of monthly infusions of α1AT to provide equivalent lower respiratory tract protection against neutrophil elastase. Intravenous infusion of 250 mg/kg of α1AT at 28-day intervals to nine individuals with α1AT deficiency and emphysema was carried out for 12 months. Serum α1AT levels exceeded the protective threshold for an average of 25 days after each dose of α1AT was administered. Furthermore, the postinfusion level of α1AT in the nadir lung epithelial lining fluid was fivefold greater than the preinfusion level, and the anti—neutrophil elastase capacity of the nadir epithelial lining fluid also was elevated significantly, nearly threefold above the preinfusion level. These results indicate that monthly administration of human α1AT is fully capable of adequately augmenting serum and lung α1AT levels and anti-elastase capacity and is therefore a rational alternative to weekly therapy.

Original languageEnglish
Pages (from-to)1259-1264
Number of pages6
JournalJAMA: The Journal of the American Medical Association
Volume260
Issue number9
DOIs
Publication statusPublished - 2 Sep 1988
Externally publishedYes

Fingerprint

Pancreatic Elastase
Safety
Emphysema
Intravenous Infusions
Respiratory System
Lung
Leukocyte Elastase
Therapeutics
Serum

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin Deficiency. / Hubbard, R. C.; Sellers, S.; Czerski, D.; Stephens, L.; Crystal, Ronald.

In: JAMA: The Journal of the American Medical Association, Vol. 260, No. 9, 02.09.1988, p. 1259-1264.

Research output: Contribution to journalArticle

@article{833fa2197d5342efa5fa5166e017eeff,
title = "Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin Deficiency",
abstract = "The hereditary disorder α1-antitrypsin (α1AT) deficiency results in the development of emphysema due to a diminished anti—neutrophil elastase screen of the lower respiratory tract. Specific therapy for this disorder is available in the form of weekly intravenous infusions of human plasma α1AT, which effectively reconstitute the anti-elastase screen of the lung in these individuals. In an attempt to reduce the frequency of therapy we evaluated the ability of monthly infusions of α1AT to provide equivalent lower respiratory tract protection against neutrophil elastase. Intravenous infusion of 250 mg/kg of α1AT at 28-day intervals to nine individuals with α1AT deficiency and emphysema was carried out for 12 months. Serum α1AT levels exceeded the protective threshold for an average of 25 days after each dose of α1AT was administered. Furthermore, the postinfusion level of α1AT in the nadir lung epithelial lining fluid was fivefold greater than the preinfusion level, and the anti—neutrophil elastase capacity of the nadir epithelial lining fluid also was elevated significantly, nearly threefold above the preinfusion level. These results indicate that monthly administration of human α1AT is fully capable of adequately augmenting serum and lung α1AT levels and anti-elastase capacity and is therefore a rational alternative to weekly therapy.",
author = "Hubbard, {R. C.} and S. Sellers and D. Czerski and L. Stephens and Ronald Crystal",
year = "1988",
month = "9",
day = "2",
doi = "10.1001/jama.1988.03410090091037",
language = "English",
volume = "260",
pages = "1259--1264",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "9",

}

TY - JOUR

T1 - Biochemical Efficacy and Safety of Monthly Augmentation Therapy for α1-Antitrypsin Deficiency

AU - Hubbard, R. C.

AU - Sellers, S.

AU - Czerski, D.

AU - Stephens, L.

AU - Crystal, Ronald

PY - 1988/9/2

Y1 - 1988/9/2

N2 - The hereditary disorder α1-antitrypsin (α1AT) deficiency results in the development of emphysema due to a diminished anti—neutrophil elastase screen of the lower respiratory tract. Specific therapy for this disorder is available in the form of weekly intravenous infusions of human plasma α1AT, which effectively reconstitute the anti-elastase screen of the lung in these individuals. In an attempt to reduce the frequency of therapy we evaluated the ability of monthly infusions of α1AT to provide equivalent lower respiratory tract protection against neutrophil elastase. Intravenous infusion of 250 mg/kg of α1AT at 28-day intervals to nine individuals with α1AT deficiency and emphysema was carried out for 12 months. Serum α1AT levels exceeded the protective threshold for an average of 25 days after each dose of α1AT was administered. Furthermore, the postinfusion level of α1AT in the nadir lung epithelial lining fluid was fivefold greater than the preinfusion level, and the anti—neutrophil elastase capacity of the nadir epithelial lining fluid also was elevated significantly, nearly threefold above the preinfusion level. These results indicate that monthly administration of human α1AT is fully capable of adequately augmenting serum and lung α1AT levels and anti-elastase capacity and is therefore a rational alternative to weekly therapy.

AB - The hereditary disorder α1-antitrypsin (α1AT) deficiency results in the development of emphysema due to a diminished anti—neutrophil elastase screen of the lower respiratory tract. Specific therapy for this disorder is available in the form of weekly intravenous infusions of human plasma α1AT, which effectively reconstitute the anti-elastase screen of the lung in these individuals. In an attempt to reduce the frequency of therapy we evaluated the ability of monthly infusions of α1AT to provide equivalent lower respiratory tract protection against neutrophil elastase. Intravenous infusion of 250 mg/kg of α1AT at 28-day intervals to nine individuals with α1AT deficiency and emphysema was carried out for 12 months. Serum α1AT levels exceeded the protective threshold for an average of 25 days after each dose of α1AT was administered. Furthermore, the postinfusion level of α1AT in the nadir lung epithelial lining fluid was fivefold greater than the preinfusion level, and the anti—neutrophil elastase capacity of the nadir epithelial lining fluid also was elevated significantly, nearly threefold above the preinfusion level. These results indicate that monthly administration of human α1AT is fully capable of adequately augmenting serum and lung α1AT levels and anti-elastase capacity and is therefore a rational alternative to weekly therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023784904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023784904&partnerID=8YFLogxK

U2 - 10.1001/jama.1988.03410090091037

DO - 10.1001/jama.1988.03410090091037

M3 - Article

VL - 260

SP - 1259

EP - 1264

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 9

ER -